dorsaVi Advances Smart Sensor Technology for Exoskeleton Market
dorsaVi Limited (ASX: DVL) has completed a strategic evaluation demonstrating the potential of its EMG and movement-sensing technology in the rapidly expanding exoskeleton and wearable robotics market. The analysis indicates that integrating the Company’s RRAM and neuromorphic computing technologies could significantly enhance sensor efficiency, reducing sensor requirements by 25–50%, lowering wireless data transmission volumes, and delivering more than double the battery life compared with conventional sensor architectures.
The Company is positioning itself as the “sensor-intelligence layer” within next-generation exoskeleton systems, enabling real-time detection of user movement intent before physical motion occurs. Its existing FDA-cleared sensor platform already supports applications such as gait-intent detection, gait-phase recognition, fatigue monitoring, and exoskeleton validation, creating opportunities across healthcare, rehabilitation, defence, industrial safety, and aged-care sectors.
Looking ahead, dorsaVi plans to advance its Ultra-Edge Intelligence strategy by combining sensing, computing, and memory capabilities into smart sensors capable of local decision-making. The Company believes this approach could strengthen its role in exoskeletons, prosthetics, and robotics while addressing a global exoskeleton market projected to reach US$1.79 billion by 2033.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
dorsaVi Advances Smart Sensor Technology for Exoskeleton Market
dorsaVi Limited (ASX: DVL) has completed a strategic evaluation demonstrating the potential of its EMG and movement-sensing technology in the rapidly expanding exoskeleton and wearable robotics market. The analysis indicates that integrating the Company’s RRAM and neuromorphic computing technologies could significantly enhance sensor efficiency, reducing sensor requirements by 25–50%, lowering wireless data transmission volumes, and delivering more than double the battery life compared with conventional sensor architectures.
The Company is positioning itself as the “sensor-intelligence layer” within next-generation exoskeleton systems, enabling real-time detection of user movement intent before physical motion occurs. Its existing FDA-cleared sensor platform already supports applications such as gait-intent detection, gait-phase recognition, fatigue monitoring, and exoskeleton validation, creating opportunities across healthcare, rehabilitation, defence, industrial safety, and aged-care sectors.
Looking ahead, dorsaVi plans to advance its Ultra-Edge Intelligence strategy by combining sensing, computing, and memory capabilities into smart sensors capable of local decision-making. The Company believes this approach could strengthen its role in exoskeletons, prosthetics, and robotics while addressing a global exoskeleton market projected to reach US$1.79 billion by 2033.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au